Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with
relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).